Mark E. Bunnage
EVP, Chief Scientific Officer · 5 filings · Latest: May 15, 2026
VERTEX PHARMACEUTICALS INC / MA
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | May 15, 2026 | Sale | $453.45 | 33 | $15.0K | 7,284 | |
VRTX | Bunnage Mark E. | — | May 15, 2026 | Proposed Sale | $453.45 | 33 | $15.0K | — | |
VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | Feb 25, 2026 | Sale | $486.35 | 620 | $301.5K | 7,284 | |
VRTX | Bunnage Mark E. | — | Feb 25, 2026 | Proposed Sale | $486.35 | 620 | $301.5K | — | |
VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | Feb 18, 2026 | Sale | $473.68 | 1,182 | $559.9K | 8,486 | |
VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | Feb 17, 2026 | Sale | $489.46 | 2,437 | $1.2M | 9,668 | |
VRTX | Bunnage Mark E. | — | Feb 18, 2026 | Proposed Sale | $473.68 | 1,182 | $559.9K | — | |
VRTX | Bunnage Mark E. | — | Feb 17, 2026 | Proposed Sale | $489.46 | 2,437 | $1.2M | — | |
VRTX | Mark E. Bunnage | EVP, Chief Scientific Officer | Feb 11, 2026 | Sale | $460.43 | 2,021 | $930.5K | 12,914 | |
VRTX | Bunnage Mark E. | — | Feb 11, 2026 | Proposed Sale | $460.43 | 2,021 | $930.5K | — |